(Q40851013)

24 September 2017

1 reference

title

GM1 ganglioside for acute ischemic stroke. Trial design issues (English)

1 reference

24 September 2017

Alter M

1

1 reference

24 September 2017

language of work or name

English

0 references

publication date

1 June 1998

1 reference

Annals of the New York Academy of Sciences

24 September 2017

published in

1 reference

24 September 2017

volume

845

1 reference

24 September 2017

page(s)

391-401

1 reference

Effect of pure bovine brain-derived gangliosides on normal human B cell proliferation in vitro

24 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.1998.TB09691.X

Design and baseline results of the monosialoganglioside early stroke trial. The EST Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.1998.TB09691.X

A bacterium lipopolysaccharide that elicits Guillain-Barré syndrome has a GM1 ganglioside-like structure

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.1998.TB09691.X

Immunopathogenesis and treatment of the Guillain-Barré syndrome--Part I.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.1998.TB09691.X

Purification of non-infectious ganglioside preparations from scrapie-infected brain tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.1998.TB09691.X

Tissue plasminogen activator for acute ischemic stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.1998.TB09691.X

10.1111/J.1749-6632.1998.TB09691.X

21 January 2018

Identifiers

DOI

1 reference

24 September 2017

1 reference